A gene therapy gel for a blistering skin disease developed at Stanford Medicine has worked wonders in a double-blind, placebo-controlled clinical trial.
The gel, called B-VEC, was intended to treat dystrophic epidermolysis bullosa, a skin disease that results in large open wounds that last for decades. The condition is extremely painful, and the medical treatment is mostly limited to palliative care.
Comments are closed.